Indeterminate diagnoses of atypia are less helpful to clinicians. Our urologic pathologists understand that definitive diagnoses are critical for optimal patient care.
Urinary cytology is a noninvasive and cost-effective diagnostic and surveillance test in clinical management of urothelial carcinoma. The Paris System for Reporting Urinary Cytology, published in 2016, introduced definitive diagnostic criteria that aimed to improve performance in detecting high-grade urothelial carcinoma and decreasing the indeterminate (atypical) diagnosis.
Our atypical rate dropped from 29% to 6%
Inform Diagnostics’ team of urologic pathologists began implementing the Paris System in 2015 after it was presented in a national cytology conference. Now our large-scale urinary cytology study of more than 27,000 cases has been published in Cancer Cytopathology*, showing Inform Diagnostics’ quality improvement.
Atypical urothelial cells correlation with a positive UroVysion® test improved from 17% to 38%
Specificity of atypical diagnosis to detect high-grade urothelial carcinoma improved from 49% to 86%
* For more information about this study, please contact us.